Neoadjuvant Chemoradiation vs Surgery Alone for Esophageal Cancer
Author Information
Author(s): van Heijl M, van Lanschot JJB, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BPL, Tilanus HW, Richel DJ, Busch ORC, Bartelsman JF, Koning CCE, Offerhaus GJ, van der Gaast A
Primary Institution: Academic Medical Center, Amsterdam, The Netherlands; Erasmus Medical Center, Rotterdam, The Netherlands
Hypothesis
Does neoadjuvant chemoradiotherapy improve survival compared to surgery alone in patients with esophageal cancer?
Conclusion
The study aims to determine if neoadjuvant chemoradiotherapy followed by surgery improves survival and quality of life compared to surgery alone.
Supporting Evidence
- Esophageal cancer has a low 5-year survival rate of 10%.
- Approximately 30% of patients with resectable disease have irradical resections.
- Neoadjuvant chemotherapy may improve survival and resectability rates.
Takeaway
This study is trying to find out if giving patients chemotherapy and radiation before surgery helps them live longer than just having surgery.
Methodology
A multicenter, randomized phase III trial comparing neoadjuvant chemoradiotherapy followed by surgery with surgery alone in patients with potentially curable esophageal cancer.
Limitations
The study may have limitations related to the generalizability of results due to the specific patient population and treatment protocols.
Participant Demographics
Patients with histologically proven squamous cell carcinoma or adenocarcinoma of the esophagus or gastro-esophageal junction.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website